Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Michael Schlander, Silvio Garattini, Peter Kolominsky-Rabas, Erik Nord, Ulf Persson, Maarten Postma, Jeff Richardson, Steven Simoens, Oriol de Solà-Morales, Keith Tolley & Mondher Toumi. (2016) Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement. Journal of Market Access & Health Policy 4:1.
Read now
Read now
Michael Schlander, Charles Christian Adarkwah & Afschin Gandjour. (2015) Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe. Expert Review of Pharmacoeconomics & Outcomes Research 15:1, pages 171-179.
Read now
Read now
Andrea Caputo. (2014) Exploring quality of life in Italian patients with rare disease: a computer-aided content analysis of illness stories. Psychology, Health & Medicine 19:2, pages 211-221.
Read now
Read now
Eline Picavet, David Cassiman & Steven Simoens. (2013) Do ultra-orphan medicinal products warrant ultra-high prices? A review. Orphan Drugs: Research and Reviews 3, pages 23-31.
Read now
Read now
Jan-Cédric Hansen. (2012) Rare Diseases and Orphan Drugs: A comprehensive approach of strategic perspectives. Journal of Communication in Healthcare 5:4, pages 199-219.
Read now
Read now
Alain Denis, Lut Mergaert, Christel Fostier, Irina Cleemput & Steven Simoens. (2010) Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. Journal of Medical Economics 13:2, pages 295-301.
Read now
Read now
Articles from other publishers (33)
Małgorzata Skweres-Kuchta, Iwona Czerska & Elżbieta Szaruga. (2023) Literature Review on Health Emigration in Rare Diseases—A Machine Learning Perspective. International Journal of Environmental Research and Public Health 20:3, pages 2483.
Crossref
Crossref
Xinye Qi, Jiao Xu, Linghan Shan, Ye Li, Yu Cui, Huan Liu, Kexin Wang, Lijun Gao, Zheng Kang & Qunhong Wu. (2021) Economic burden and health related quality of life of ultra-rare Gaucher disease in China. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Bettina M. Zimmermann, Johanna Eichinger & Matthias R. Baumgartner. (2021) A systematic review of moral reasons on orphan drug reimbursement. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Han Steutel. 2021. Arzneimittel-Kompass 2021. Arzneimittel-Kompass 2021
209
223
.
Karolina Pierzynowska, Teresa Kamińska & Grzegorz Węgrzyn. (2020) One drug to treat many diseases: unlocking the economic trap of rare diseases. Metabolic Brain Disease 35:8, pages 1237-1240.
Crossref
Crossref
Mauricio De Castro, Clesson Turner & Brian Kirmse. (2020) Practical recommendations for the transition to adulthood for the adolescent with a genetic diagnosis. Special emphasis on inborn errors of metabolism. Translational Science of Rare Diseases 4:3-4, pages 159-168.
Crossref
Crossref
Mehmet Umut Akyol, Tord D. Alden, Hernan Amartino, Jane Ashworth, Kumar Belani, Kenneth I. Berger, Andrea Borgo, Elizabeth Braunlin, Yoshikatsu Eto, Jeffrey I. Gold, Andrea Jester, Simon A. Jones, Cengiz Karsli, William Mackenzie, Diane Ruschel Marinho, Andrew McFadyen, Jim McGill, John J. Mitchell, Joseph Muenzer, Torayuki Okuyama, Paul J. Orchard, Bob Stevens, Sophie Thomas, Robert Walker, Robert Wynn, Roberto Giugliani, Paul Harmatz, Christian Hendriksz & Maurizio Scarpa. (2019) Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. Orphanet Journal of Rare Diseases 14:1.
Crossref
Crossref
Sumika Toyama, Ohsuke Migita, Masayuki Fujino, Tetsuo Kunieda, Motomichi Kosuga, Yasuyuki Fukuhara, Yukitoshi Nagahara, Xiao‐Kang Li & Torayuki Okuyama. (2019)
Liver transplantation: New treatment for mucopolysaccharidosis type
VI
in rats
. Pediatrics International 61:2, pages 180-189.
Crossref
Crossref
Michael Schlander, Charalabos-Markos Dintsios & Afschin Gandjour. (2018) Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases. Value in Health 21:5, pages 525-531.
Crossref
Crossref
Rita Ferla, Marialuisa Alliegro, Jean-Brice Marteau, Margherita Dell’Anno, Edoardo Nusco, Severine Pouillot, Stefania Galimberti, Maria Grazia Valsecchi, Vincent Zuliani & Alberto Auricchio. (2017) Non-clinical Safety and Efficacy of an AAV2/8 Vector Administered Intravenously for Treatment of Mucopolysaccharidosis Type VI. Molecular Therapy - Methods & Clinical Development 6, pages 143-158.
Crossref
Crossref
Tineke Kleinhout-Vliek, Antoinette de Bont & Bert Boer. (2017) The bare necessities? A realist review of necessity argumentations used in health care coverage decisions. Health Policy 121:7, pages 731-744.
Crossref
Crossref
Marialuisa Alliegro, Rita Ferla, Edoardo Nusco, Chiara De Leonibus, Carmine Settembre & Alberto Auricchio. (2016) Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease. Molecular Therapy 24:12, pages 2054-2063.
Crossref
Crossref
Márta Péntek, László Gulácsi, Valentin Brodszky, Petra Baji, Imre Boncz, Gábor Pogány, Julio López-Bastida, Renata Linertová, Juan Oliva-Moreno, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, Domenica Taruscio, Georgi Iskrov, Arrigo Schieppati, Johann Matthias Graf von der Schulenburg, Panos Kanavos, Karine Chevreul, Ulf Persson & Giovanni Fattore. (2016) Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. The European Journal of Health Economics 17:S1, pages 89-98.
Crossref
Crossref
Maurizio Scarpa, Cinzia Bellettato & Christina Lampe. 2016. Drug Discovery and Evaluation: Pharmacological Assays. Drug Discovery and Evaluation: Pharmacological Assays
4053
4069
.
Laura Gutierrez, Julien Patris, Adam Hutchings & Warren Cowell. (2015) Principles for consistent value assessment and sustainable funding of orphan drugs in Europe. Orphanet Journal of Rare Diseases 10:1.
Crossref
Crossref
Aris Angelis, David Tordrup & Panos Kanavos. (2015) Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy 119:7, pages 964-979.
Crossref
Crossref
Maurizio Scarpa, Cinzia Bellettato & Christina Lampe. 2014. Drug Discovery and Evaluation: Pharmacological Assays. Drug Discovery and Evaluation: Pharmacological Assays
1
20
.
Michael Schlander, Silvio Garattini, Søren Holm, Peter Kolominsky-Rabas, Erik Nord, Ulf Persson, Maarten Postma, Jeff Richardson, Steven Simoens, Oriol de Solà Morales, Keith Tolley & Mondher Toumi. (2014) Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. Journal of Comparative Effectiveness Research 3:4, pages 399-422.
Crossref
Crossref
Rita FerlaPamela ClaudianiGabriella CotugnoPaola SacconeElvira De LeonibusAlberto Auricchio. (2014) Similar Therapeutic Efficacy Between a Single Administration of Gene Therapy and Multiple Administrations of Recombinant Enzyme in a Mouse Model of Lysosomal Storage Disease. Human Gene Therapy 25:7, pages 609-618.
Crossref
Crossref
Eline Picavet, Thomas Morel, David Cassiman & Steven Simoens. (2014) Shining a light in the black box of orphan drug pricing. Orphanet Journal of Rare Diseases 9:1, pages 62.
Crossref
Crossref
Sandra Jester, Julia Larsson, Erik A Eklund, Domniki Papadopoulou, Jan-Eric Månsson, Albert N Békássy, Dominik Turkiewicz, Jacek Toporski & Ingrid Øra. (2013) Haploidentical stem cell transplantation in two children with mucopolysaccharidosis VI: clinical and biochemical outcome. Orphanet Journal of Rare Diseases 8:1.
Crossref
Crossref
Anuradha Ganesh, Zandre Bruwer & Khalid Al-Thihli. (2013) An update on ocular involvement in mucopolysaccharidoses. Current Opinion in Ophthalmology 24:5, pages 379-388.
Crossref
Crossref
Eun Cho, Eun-Cheol Park & Myoung Sheen Kang. (2013) Pitfalls in Reimbursement Decisions for Oncology Drugs in South Korea: Need for Addressing the Ethical Dimensions in Technology Assessment. Asian Pacific Journal of Cancer Prevention 14:6, pages 3785-3792.
Crossref
Crossref
Jennifer A. GorzelanyMark P. de Souza. (2013) Protein Replacement Therapies for Rare Diseases: A Breeze for Regulatory Approval?. Science Translational Medicine 5:178.
Crossref
Crossref
Wilcken Bridget. (2012) Screening for disease in the newborn: the evidence base for blood-spot screening. Pathology 44:2, pages 73-79.
Crossref
Crossref
Joseph Muenzer, Olaf Bodamer, Barbara Burton, Lorne Clarke, Gudrun Schulze Frenking, Roberto Giugliani, Simon Jones, Maria Verónica Muñoz Rojas, Maurizio Scarpa, Michael Beck & Paul Harmatz. (2011) The role of enzyme replacement therapy in severe Hunter syndrome—an expert panel consensus. European Journal of Pediatrics 171:1, pages 181-188.
Crossref
Crossref
EMILY A. LARGENT & STEVEN D. PEARSON. (2014) Which Orphans Will Find a Home? The Rule of Rescue in Resource Allocation for Rare Diseases. Hastings Center Report 42:1, pages 27-34.
Crossref
Crossref
Pamela Holtzclaw Williams. (2011) Policy Framework for Rare Disease Health Disparities. Policy, Politics, & Nursing Practice 12:2, pages 114-118.
Crossref
Crossref
Gabriella Cotugno, Patrizia Annunziata, Alessandra Tessitore, Thomas O'Malley, Anita Capalbo, Armida Faella, Rosa Bartolomeo, Patricia O'Donnell, Ping Wang, Fabio Russo, Meg M Sleeper, Van W Knox, Steven Fernandez, Leah Levanduski, John Hopwood, Elvira De Leonibus, Mark Haskins & Alberto Auricchio. (2011) Long-term Amelioration of Feline Mucopolysaccharidosis VI After AAV-mediated Liver Gene Transfer. Molecular Therapy 19:3, pages 461-469.
Crossref
Crossref
Alain Denis, Lut Mergaert, Christel Fostier, Irina Cleemput & Steven Simoens. (2010) Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe. Applied Health Economics and Health Policy 8:5, pages 343-350.
Crossref
Crossref
Ciaran O’Neill. (2010) How can the risk that orphan drugs present to budgets be managed better?. Clinical Therapeutics 32:9, pages 1640-1641.
Crossref
Crossref
Gregory M Pastores. (2010) Galsulfase: enzyme therapy for mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome). Pediatric Health 4:1, pages 17-24.
Crossref
Crossref
Bryan A. LiangTim Mackey. (2010) Reforming Off-Label Promotion to Enhance Orphan Disease Treatment. Science 327:5963, pages 273-274.
Crossref
Crossref